Supplementary Table 1A Characteristics of studies with by pengxuebo

VIEWS: 3 PAGES: 39

									Supplemental Table 1: Description of Variables assessed in the studies included (in which
        initial diagnoses and outcomes were all microbiologically confirmed)

            Variable                                    Studies   Arms
                                                        (N)       (N)
            TOTAL                                       27        40

            Design
            RCT - varying rifampin duration             3         7
            RCT – not addressing rifampin duration1     3         5
            Cohort studies                              21        28

            Outcomes Reported
            Failure                                     27        40
            Relapse                                     17        24
            Deaths during treatment                     27        40

            Resistance
            Pan-sensitive                               9         14
            Sensitive and resistant, excluding MDRTB    5         8
            Only drug resistant, MDRTB excluded         1         2
            Sensitive and resistance, MDRTB not         2         2
            specified
            Not specified                               12        14

            Treatment History
            New cases only                              21        32
            Retreatment cases only                      2         3
            Both new and retreatment                    3         3
            Not specified                               1         2

            Site of TB
            Pulmonary only                              24        36
            Either pulmonary or extra-pulmonary         3         4

            Duration of Rifampin                        3

            2 months                                    10        12
            6 months (1 study/arm with Rifabutin)       16        19
            8 months or more (Total)                    7         9
                8 months                                3         4
                9 months                                3         4
                12 months                               1         1

            Dosing schedule
            Daily in intensive phase2                   23        35
            Intermittent in intensive phase (3X/week)   4         5

            DOT
                     Throughout                                              6                10
                     None or partial or not specified                        21               30

                     ARV Use
                     All patients on ARV                                     4                6
                     Some patients on ARV                                    2                3
                     No patients on ARV                                      10               14
                     Not specified (many in pre-ARV era)                     11               17

                     QUALITY ASSESSMENT
                     Completion of treatment                                 4

                     ≤ 10% lost/defaulted                                    16               23
                     > 10% lost/defaulted                                    15               17
                     Completion of follow-up post
                     treatment-
                     ≤ 10% lost/defaulted                                    8                11
                     > 10% lost/defaulted                                    5                9
                     Not reported                                            4                4


1 One trial assessed ciprofloxacin in the treatment of active TB; one trial assessed the addition of M. vaccae we included only
the placebo arm; one trial compared a rifabutin-containing regimen to a rifampin-containing regimen.
2 When the dosing schedule was not specified, it was assumed that therapy was given daily. This was done as 4 arms were

from Malawi and Brazil, where daily treatment is recommended.
3 Adds up to more than 27 because some studies used more than one duration
4 Adds up to more than 27 because studies had some arms with >10, and some with <10%
Supplemental Table 2. Results from studies with head-to-head comparisons of different durations of rifampin, or dosing
schedules. All studies enrolled newly diagnosed, culture-positive patients with pulmonary TB.

Ref      Country      Year1     # of        # of      Initial Drug-     Treatment         Dose schedule        ART       Mortality     Failure Rate3      Relapse Rate3
                                arms      patients     Resistance2                        (days/week for       use        during
                                                                                              Initial,                  treatment3
                                                                                           Continuation)
 a       United        1995       2          51            PS         2HRZE/4HR                 3, 2           Some       12.2%            2.3%               5.9%
         States                              50                       2HRZE/7HR                                           22.9%             0%                6.7%
 b      Multiple4      2001       3          44           Mix         2HRZE/6HE                 7, 7            Not       20.5%            8.6%               26.1%
                                             44                       2HRZE/6HE                 3, 7           Spec-       5.4%            5.7%                25%
                                             36                       2HRZE/4HR                 7, 7           ified      12.9%              0                  0%
 c        Zaire        1991       2         167           Mix         2HRZE/10HR                7, 2            No        26.0%5           4.0%                1.7%
                                            168                       2HRZE/4HR                                           14.5%            4.0%               13.2%


a. El Sadr WM et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related
pulmonary tuberculosis. Clin Infect Dis. 1998 May;26(5):1148-58.
b. Jindani A et al. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
Lancet. 2004 Oct 2-8;364(9441):1244-51.
c. Perriens J et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. The New England Journal of
Medicine. 1995 Mar;332(12):779-84.
1 The year in which enrolment of patients ended.
2 Drug resistance of initial isolates: PS = pan susceptible; Mix = Mixed sensitivities
3 Mortality during treatment calculated excluding patients lost to follow-up. Failure and relapse calculated excluding patients lost to follow-up and deaths.
4 Calculations from data provided by authors for only HIV-positive patients.
5 Patients were randomized to either 6 or 12 months of treatment after successful completion of 6 months of therapy. For the 12 month arm, mortality rates shown

are during the last 6 months of treatment and include deaths during follow-up. For the 6 month arm, rates shown are mortality while on-treatment
                                                                                    Supplementary Table 3A: Characteristics of studies with standardized treatment regimens that did not have full microbiological
                                                                                                               confirmation of either tuberculosis diagnosis or treatment outcomes


Ref   Country        Year1           Study             # of arms        # of patients         TB         % of confirmed            % of confirmed           Treatment          Initial        Rifamycin        Dose schedule          ART use         Outcomes     Duration of   % lost    % lost after
                                    Design2                                                  Site3         diagnosis               failure/relapse           History4          Drug-          Duration         (days/week for                         Reported        F/U        during    treatment
                                                                                                                                                                             Resistance       (months)             Initial,                                         (months)      treat-
                                                                                                                                                                                   5                            Continuation)                                                     ment

a      Haiti         1992            Cohort                1                 158              M                  74                       NS                   New               M*                6                  3, 3               NS              F, R          22          8.2         NS
b      Cote          1998            Cohort                1                 217              M                  43                       100                  NS                NS                6                  NS                 NS              F, R           4          31          65
      d’Ivoire
 c     Haiti         1998             RCT                  1                  74               P                 22                       NS                   New               NS                6                  7, 2               No                R           25           -          34

d      Cote          1995            Cohort                1                  33              M                  16                       NS                    NS               NS                6                  NS                 No                F           0           6.1          -
      d’Ivoire
 e     Haiti         1995            Cohort                1                  39              M                  46             No failures.                     M               NS                11                 7, 7               NS                F           0           46           -

 f     India         2002            Cohort                1                  86              M                  28             No failures.                   New               NS                9                  NS                 All              F,R          69          0           13

 g     India         1998            Cohort                2                   7              M                  71             No failures in either           R                NS                8                  3, 3               No                F           0           14           -
                                                                              11                                 45             arm.                           New                                 6                  3, 3               No                F           0            9           -

      a: Chaisson RE et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996 Oct; 154 (4 Pt 1):1034-8.
      b: Eholie SP et al. [Outcome of patients with tuberculosis and AIDS in Abidjan (Ivory Coast)]. Medecine et Maladies Infectieuses.1999; 29(11):697-704.
      c: Fitzgerald DW et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet. 2000 Oct 28; 356(9240):1470-4.
      d: Mukadi YD et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS. 1997 Jul 15; 11(9):1151-8.
      e: Olle-Goig JE, Alvarez J. Treatment of tuberculosis in a rural area of Haiti: Directly observed and non-observed regimens. The experience of Hopital Albert Schweitzer. International Journal of Tuberculosis and Lung Disease, 2001;5(2):137-41.
      f: Patel A et al. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are co-infected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1166-9.
      g: Rodger AJ et al. DOTS-based tuberculosis treatment and control during civil conflict and an HIV epidemic, Churachandpur District, India. Bull World Health Organ. 2002; 80(6):451-6.
      1 The year in which enrolment of patients ended.
      2 Study design: RCT = randomized controlled trial
      3 Site of infection: P = pulmonary only; M = pulmonary and extrapulmonary
      4 History of previous TB treatment: Retreat = retreatment; Mix = both new and retreatment patients; NS = Not specified
      5 Drug resistance of initial isolates: M* = mixed sensitivities including 3 patients with MDR; NS = Not specified

      - = Not applicable
      NS = Not specified
Supplementary Table 3B: Description of variables assessed in studies in which some
patients were diagnosed clinically

            Variable                                 Studies   Arms
                                                     (N)       (N)
            TOTAL                                    7         8

            Design
            RCT - varying rifampin duration          0         0
            RCT – not addressing rifampin duration   1         1
            Cohort studies                           6         7

            Outcomes Reported
            Failure                                  6         7
            Relapse                                  4         4
            Deaths during treatment                  6         7

            Resistance
            Not specified                            6         7
            Mixed plus 3 MDR patients                1         1

            Treatment History
            New cases only                           4         4
            Retreatment cases only                   1         1
            Both new and retreatment                 1         2
            Not specified                            1         1
            Site of TB
            Pulmonary only                           1         1
            Either pulmonary or extra-pulmonary      6         7

            Duration of Rifampin
            2 months                                 0         0
            6 months (1 study/arm with Rifabutin)    5         5
            8 months or more (Total)                 3         3
            Dosing schedule
            Daily in intensive phase                 2         2
            Intermittent in intensive phase          3         3
                 3 times weekly                      3         3

            DOT
            Throughout (All doses)                   2         3
            None or partial or not specified         5         5

            ARV Use
            All patients on ARV                      1         1
            Some patients on ARV                     0         0
No patients on ARV                    3   4
Not specified (many in pre-ARV era)   3   3

QUALITY ASSESSMENT
Completion of treatment
≤ 10% lost/defaulted                  4   4
> 10% lost/defaulted                  3   3
Completion of follow-up post
treatment-
≤ 10% lost/defaulted                  0   0
> 10% lost/defaulted                  3   3
Not reported                          1   1
 Supplementary Table 4: Pooled Estimates of Major Outcomes Stratified by Quality
                         of Diagnosis (All Studies Compared)

Outcome                              Arms       Events/Subjects        Pooled     (95% CI)
                                      (N)             (N)              Event
                                                                        rate
FAILURE
   Poor                                8              6/415             1.1%        (0, 2.4)
   Good                                40            86/2690            2.6%       (1.5, 3.7)

RELAPSE
  Poor                                 4             25/266             6.7%       (0, 18.6)
  Good                                 24           160/1302            8.1%      (1.0, 15.3)

DEATH DURING TREATMENT
  Poor                 8                             72/487            13.0%      (3.9, 22.2)
  Good                40                            461/3151           11.6%      (7.6, 15.7)


Quality of diagnosis judged as:
‘Good’ if all patients had microbiologically confirmed (smear and/or culture positive) active
TB at entry to the study, and all failures or relapses were also microbiologically confirmed.

‘Poor’ was defined as some patients had clinical diagnoses initially, although at least some
were confirmed microbiologically. Failure and/or relapse may or may not have been
confirmed microbiologically in these studies.
     Supplementary Table 5: Pooled estimates of major outcomes only in Studies that
                    utilized clinical diagnoses (Secondary analysis)

                                     5A: Rifamycin duration
Outcome                                   Arms     Events/Subjects          Pooled     (95% CI)
                                           (N)            (N)               Event
                                                                             rate
FAILURE
  Rifamycin 2 months                          0               -                -            -
  Rifamycin 6 months                          4             6/279            1.9%       (0.3, 3.6)
  Rifamycin ≥9 months                         3             0/102             1%         (0, 10)

RELAPSE
  Rifamycin 2 months                          0               -                -            -
  Rifamycin 6 months                          3            19/194            7.5%       (0, 19.7)
  Rifamycin ≥ 9 months                        1             6/72             7.8%       (0, 27.3)

DEATH DURING TREATMENT
  Rifamycin 2 months                          0               -                -            -
  Rifamycin 6 months                          4            57/336           17.9%        (0, 38)
  Rifamycin ≥ 9 months                        3            11/113            9.3%        (0, 25)



                            5B: Schedule of administration initially
Outcome                                  Arms     Events/Subjects            Pooled     (95% CI)
                                          (N)            (N)                 Event
                                                                              rate
FAILURE
  Daily **                                    4              3/236            1.7%       (0, 3.3)
  Intermittent ***                            3              3/145            3.9%      (0.7, 7.1)

RELAPSE
  Daily **                                    3             18/137            9.2%       (0, 22.9)
  Intermittent ***                            1             7/129             5.1%       (0, 17.2)

DEATH DURING TREATMENT
  Daily **                                    4             52/288           15.1%        (0, 34)
  Intermittent ***                            3             16/161           12.0%        (0, 34)

   ** Daily initially followed by daily or intermittent in continuation phase.
   *** 2 studies (2 arms) used twice weekly, and 4 studies (5 arms) used thrice weekly in the
   initial intensive phase.
    Supplementary Table 5: Pooled estimates of major outcomes only in Studies that
                   utilized clinical diagnoses (Secondary analysis)

            5C: Use of Anti-retroviral Therapy (ART) during TB treatment
Outcome                                Arms     Events/Subjects Pooled      (95% CI)
                                        (N)           (N)         Event
                                                                   rate
FAILURE
  No                                   6            6/295          1.3%      (0, 2.6)
  Yes                                  1             0/86           0%        (0, 12)

RELAPSE
  No                                   3           19/194          7.5%     (0, 19.7)
  Yes                                  1            6/72           7.8%     (0, 27.3)

DEATH DURING TREATMENT
  No                                   6           68/363         22.0%      (11, 33)
  Yes                                  1            0/86            0%       (0, 12)
Appendix I. Search strategies
Medline (searched from 1950-April 2008)
1. exp hiv/ or exp hiv infections/
2. (hiv or aids or acquired immunodefic or acquired immune deficinc$).ti,ab.
3. exp Tuberculosis/dt [Drug Therapy]
4. exp Antitubercular Agents/tu [Therapeutic Use]
5. (tuberculos$ or antitubercul$).ti,ab.
6. (1 or 2) and (3 or 4 or 5)
7. controlled clinical trial.pt.
8. randomized controlled trial.pt.
9. Randomized Controlled Trials/
10. Random Allocation/
11. Double-Blind Method/
12. Single-Blind Method/
13. or/7-12
14. Animal/ not Human/
15. 13 not 14
16. clinical trial.pt.
17. (clinic$ adj25 trial$).tw.
18. exp Clinical Trial/
19. ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.
20. Placebos/
21. placebo$.tw.
22. random$.tw.
23. Research Design/
24. (latin adj square).tw.
25. or/16-24
26. 25 not 14
27. 26 not 15
28. Comparative Study/
29. exp Evaluation Studies/
30. Follow-Up Studies/
31. Prospective Studies/
32. (control$ or prospectiv$ or volunteer$).tw.
33. Cross-Over Studies/
34. or/28-33
35. 34 not 14
36. 35 not (15 or 27)
37. 15 or 27 or 36

Embase (searched from 1988 – April 2008)
1. exp hiv/ or exp hiv infections/
2. (hiv or aids or acquired immunodefic or acquired immune deficinc$).ti,ab.
3. exp Tuberculosis/dt [Drug Therapy]
4. exp Antitubercular Agents/tu [Therapeutic Use]
5. (tuberculos$ or antitubercul$).ti,ab.
6. (1 or 2) and (3 or 4 or 5)
7. controlled clinical trial.pt.
8. randomized controlled trial.pt.
9. Randomized Controlled Trials/
10. Random Allocation/
11. Double-Blind Method/
12. Single-Blind Method/
13. or/7-12
14. Animal/ not Human/
15. 13 not 14
16. clinical trial.pt.
17. (clinic$ adj25 trial$).tw.
18. exp Clinical Trial/
19. ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.
20. Placebos/
21. placebo$.tw.
22. random$.tw.
23. Research Design/
24. (latin adj square).tw.
25. or/16-24
26. 25 not 14
27. 26 not 15
28. Comparative Study/
29. exp Evaluation Studies/
30. Follow-Up Studies/
31. Prospective Studies/
32. (control$ or prospectiv$ or volunteer$).tw.
33. Cross-Over Studies/
34. or/28-33
35. 34 not 14
36. 35 not (15 or 27)
37. 15 or 27 or 36
38. 6 and 37

Cochrane Central Register of Controlled Trials (searched database up to and including first
quarter 2008)
1. exp hiv/ or exp hiv infections/
2. (hiv or aids or acquired immunodefic$ or acquired immuno defic$ or acquired
immunedefic$ or acquired immune defic$).ti,ab.
3. exp Tuberculosis/dt [Drug Therapy]
4. exp Antitubercular Agents/tu [Therapeutic Use]
5. (tuberculosis or antitubercular).ti,ab.
6. (1 or 2) and (3 or 4 or 5)
7. (clinical conference or clinical trial, all or clinical trial, phase i or clinical trial, phase ii or
clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or
consensus development conference or consensus development conference, nih or controlled
clinical trial or evaluation studies or guideline or meta analysis or multicenter study or
practice guideline or randomized controlled trial or "scientific integrity review" or validation
studies).pt.
8. exp study characteristics/ or exp epidemiologic study characteristics as topic/
9. exp epidemiologic research design/ or exp research design/
10. placebos/ or placebo effect/
11. exp longitudinal studies/
12. exp treatment outcome/
13. (clinical and trial$1).ti,ab.
14. ((single or double or triple or treble) and (blind$ or mask$)).ti,ab.
15. (random$ or control$ or prospective or volunteer$ or placebo$).ti,ab.
16. or/7-15
17. 6 and 16
18. (randomized controlled trial or controlled clinical trial).pt.
19. exp Controlled Clinical Trials as Topic/
20. 14 or 15 or 18 or 19
21. 6 and 20
22. exp human immunodeficiency virus/ or exp Human Immunodeficiency Virus Infection/
23. (hiv or aids or acquired immunodefic or acquired immune deficinc$).ti,ab.
24. exp Tuberculosis/dr, dt [Drug Resistance, Drug Therapy]
25. exp Tuberculostatic Agent/
26. (tuberculos$ or antitubercul$).ti,ab.
27. (22 or 23) and (24 or 25 or 26)
28. exp controlled clinical trial/ or exp randomization/
29. exp single blind procedure/ or exp double blind procedure/
30. exp clinical trial/
31. placebo/
32. exp methodology/ or comparative study/ or evaluation/ or follow up/ or prospective
study/
33. ((control$ or clinical or random$) and trial$).mp.
34. ((singl$ or doubl$ or tripl$ pr treble) and (blind$ or mask$)).mp.
35. (placebo$ or random$ or control$ or prospectiv$ or volunteer$).mp.
36. or/28-35
37. 27 and 36
38. 17 or 37
                  Appendix II HIV-TB DATA EXTRACTION FORM
                              1- Screening for Eligibility
Reviewer:                                                Endnote ID:
Author:                                Journal                            Year 1st Pub'n:            Papers (N):

Language:         English     French       Spanish

Design:                RCT            Cohort     Prospective                   Retrospective
                       CaseControl    Prevalence    Modeling                   Cost effectiveness
                       Other_________________

TB Treatment regimens:         Standardized          Individualized         Not Drug Therapy    No treatment

          If Standardized:             Number of different regimens: ________


          If more than 1:              Outcomes by regimen:           Yes         No


Patients with HIV:                                                    -
                                       Outcomes by HIV status:
Treatment Outcomes:
    BACTERIOLOGIC:

    Non-BACTERIOLOGIC:


    How was non-bacteriologic failure defined:

D.S.T
          If D.S.T

Types of Patients
        Active TB
        ART:
                             Outcomes

          Site:                                                                  -pulmonary only


          Treatment history:

                                       If mixed/all -
        Drug resistance                         Sens & any form of resistance                       only
                                             only -all types                  -                            only




Reasons:
                                 2 – Assessment of Quality (If included)

How complete is reporting:



 Started on treatment /entered study (Total)
 Excluded for Side effects, pregnancy, Not TB, NTM,
 other valid reasons

 Treated and eligible for outcomes analysis

 During Treatment
 Non-compliant/ Refused
 Dropped out/ Lost
 Transfer out/ Moved
 Protocol violation/ Incomplete data
 Sub-total - Not analyzed for Study problems


 Died during treatment
 Completed treatment, cured of failed


 After Treatment (If follow-up or relapse)
 Duration of follow-up after treatment (mean or median
 in months)


 Lost to follow-up (AFTER end of Tx)

 Completed follow-up (or relapsed TB or died)

Other quality indicators:
If RCT:
Randomization?


If Cohort:
Patient selection:                                                    ample

Determinant of allocation to regimen:                                           -choice


If “clinical” outcomes:
     Were
     If independent -
Was there potential bias - in selecting patients for inclusion?
Were any patients excluded for analysis?
Selection bias - were included/excluded patients characteristics described?
                                                                Adjusted for?
Did all patients have either smear positive or culture/histologically confirmed TB?

       If NO: % patients with smear pos/culture pos/histologically confirmed TB
__________
       If NO: Were authors able to provide data for only the patients with confirmed TB
                               3 – Study Description (If included)


       Sponsor

       HIV%:          _______ %
       CD4:           _______ (mean)                ______(median)
       Age:           _______(mean)                 ___
       % Male
       % Pulmonary
       % Smear positive

        Treatment regimens:
        Was Rifamycin of varying duration? Y           N
               Were outcomes stratified by RIF duration?
        Was rifabutin used?                        Were outcomes stratified by RBT use?
        Intermittent?              Outcomes stratified by intermittent?
                                      1                2                  3               4
Abbreviation (HRZE)
Duration of entire Rx
Mean duration of Rx (range)
Frequency ( 2 3 5 7 )
  Initial
  Continuation
Supervision ( Y N NS )
  Initial
  Continuation
FDC used ( Y N NS )
  Initial
  Continuation
RIF months (0 – 12)
RBT months (0 – 12)
PZA months (0 – 12)
STREP months (0 – 12)
INH months (0 – 12)
ETH months (0-12)
THA months (0 – 12)
N drugs – initial
N drugs – continuation
ART (Y or N)
     If ART: Regimen
     # pts on ART
    4 – Outcomes
Treatment ____:   Initially sensitive

____ Treated         ____ Deaths          _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS      ____ SDR ____ PDR      ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS        ____ SDR   ____ PDR    ____ MDR
___RMR

Treatment ____:   Initially sensitive
                                    ART ______________
____ Treated         ____ Deaths          _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS      ____ SDR ____ PDR      ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS        ____ SDR   ____ PDR    ____ MDR
___RMR

Treatment ____:   Initially sensitive

____ Treated         ____ Deaths          _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS      ____ SDR ____ PDR      ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS        ____ SDR   ____ PDR    ____ MDR
___RMR

Treatment ____:   Initially sensitive

____ Treated         ____ Deaths          _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS      ____ SDR ____ PDR      ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS        ____ SDR   ____ PDR    ____ MDR
___RMR

Treatment ____:   Initially sensitive
                                                           Mixed (ART and No ART)
____ Treated         ____ Deaths          _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS      ____ SDR ____ PDR      ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS        ____ SDR   ____ PDR    ____ MDR
___RMR
Treatment ____:   Initially sensitive

____ Treated         ____ Deaths        _____ Adv Rx

____ Denom. F ____ Cured    ____ Failed → ____ SENS    ____ SDR ____ PDR     ____ MDR
___RMR

____ Denom. R              ____ Relapse→____ SENS      ____ SDR   ____ PDR   ____ MDR
___RMR
            Supplementary Table 6. Reasons for exclusion of articles assessed in full-text review
  First Author     Year             Journal                                     Title                                                         Assessment

                          Central African Journal of     Pleural tuberculosis in patients infected with HIV     Outcomes not stratified by treatment regimen; inadequate information
Aderaye, A.        1996   Medicine                       in Addis Ababa                                         on treatment regimens used.
                          International Journal of
                          Tuberculosis & Lung            The epidemiological profile of tuberculosis in         Outcomes not stratified by treatment regimen; inadequate information
Aerts, D.          2004   Disease (IJTLD)                southern Brazil in times of AIDS                       on treatment regimens used.
                                                         Prevalence of human immunodeficiency virus
                          Pan American Journal of        infection in patients with pulmonary tuberculosis at
Akpaka, P.E.       2006   Public Health                  the National Chest Hospital in Jamaica                 Variable duration of treatment (9-15 months)
                                                         HIV infection and sputum-culture conversion in
                          Wiener Klinische               patients diagnosed with Mycobacterium
Aliyu, M. H.       2003   Wochenschrift                  tuberculosis: a population-based study                 Inadequate description of treatment regimen.
                                                         A prospective study of tuberculosis and human
                                                         immunodeficiency virus infection: clinical
Alpert, P. L.      1997   Clinical Infectious Diseases   manifestations and factors associated with survival    Neither failure nor relapse reported.

                                                         Effectiveness of supervised, intermittent therapy      Outcomes not stratified by treatment regimen (specifically duration of
Alwood, K.         1994   AIDS                           for tuberculosis in HIV-infected patients              therapy).


                                                         [Tuberculosis in African children: epidemiologic,
Anane, R.          2003   Medecine Tropicale             clinical and therapeutic aspects (corrected)]          Outcomes not given by HIV status & treatment regimens.
                                                         A controlled clinical trial of oral short-course
                                                         regimens in the treatment of sputum-positive
Anonymous          1997   IJTLD                          pulmonary tuberculosis                                 No HIV testing
                                                         Treating concurrent HIV and TB. Centers for
Anonymous          1996   AIDS Clinical Care             Disease Control and Prevention.                        Not a study
                                                         Evaluation of a non-rifampicin continuation phase
                                                         (6HE) following thrice-weekly intensive phase for
                          Indian Journal of              the treatment of new sputum positive pulmonary
Anonymous          2007   Tuberculosis                   tuberculosis                                           Only 1 pt with HIV.
                                                         [Epidemiologic follow-up of cases of tuberculosis
                          Revue des Maladies             in the medical-social centers of Paris for the year
Antoun, F.         1998   Respiratoires                  1994]                                                  Individualized treatment regimens.
                                                        [Tuberculous meningitis: a comparative study in
                         Enfermedades Infecciosas y     relation to concurrent human immunodeficiency
Azuaje, C.        2006   Microbiologia Clinica          virus infection]                                      Outcomes not stratified by treatment regimen.
                                                                                                              Outcomes not given by HIV status & treatment regimens (only
                                                        Mortality rates and recurrent rates of tuberculosis   provided outcomes for HIV positive patients, but they could have
                                                        in patients with smear-negative pulmonary             received either 2 months of rifampin or no rifampin). See also
                                                        tuberculosis and tuberculous pleural effusion who     KANGOMBE 2000, KANGOMBE 2004, HARRIES 1999 (IJTLD),
Banda, H.         2000   IJTLD                          have completed treatment                              HARRIES 1999 (TRSTMH).
                         New England Journal of         Tuberculosis in patients with human
Barnes, P. F.     1991   Medicine (NEJM)                immunodeficiency virus infection                      Review article.

                         Annales de Medecine            [Role of human immunodeficiency virus infection
Beaulieu, P.      1993   Interne                        in 67 patients with tuberculosis]                     Outcomes not stratified by treatment regimen.
                                                        Impact of human immunodeficiency virus 1
                                                        infection on clinical presentation, treatment
Berggren Palme,          Pediatric Infectious Disease   outcome and survival in a cohort of Ethiopian
I.                2002   Journal                        children with tuberculosis                            Outcomes not stratified by treatment regimen.
                         Medecine et Maladies
Bicart-See, A.    1995   Infectieuses                   [Tuberculosis characteristics during AIDS]            Outcomes not stratified by treatment regimen.

Blusse van Oud-          Annals of Tropical             Human immunodeficiency virus infection in
Alblas, H. J.     2002   Paediatrics                    children hospitalised with tuberculosis               Outcomes not stratified by treatment regimen.
                                                        [Tuberculosis and HIV co-infection among
Bobossi-                                                children hospitalized in Bangui (Central African
Serengbe, G.      2005   Archives de Pediatrie          Republic)]                                            Outcomes not stratified by treatment regimen.
                                                        Outcomes of HIV-infected children with
                                                        tuberculosis who are started on antiretroviral        Outcomes not stratified by HIV status & treatment regimens;
Bong, C. N.       2007   IJTLD                          therapy in Malawi                                     insufficient data regarding TB regimen.
                                                        Mycobacterium tuberculosis bacteremia in patients
                         Archives of Internal           with and without human immunodeficiency virus
Bouza, E.         1993   Medicine                       infection                                             Individualized treatment regimens.

                                                        Long-term outcome of inpatients with tuberculosis
                         Journal of Investigative       assigned to outpatient therapy at a local clinic in
Brainard, D.      1997   Medicine                       New Orleans                                           Individualized treatment regimens.
                           Journal of Infectious         Virological response to highly active antiretroviral   Outcomes not stratified by treatment regimen; variable duration of
Breen, R.           2006   Diseases                      therapy is unaffected by antituberculosis therapy      treatment. SEE ALSO BREEN 2004

                                                         Paradoxical reactions during tuberculosis treatment
Breen, R. A.        2004   Thorax                        in patients with and without HIV co-infection          Outcomes of interest not reported.
                                                         Infection and morbidity in patients with
Brindle, R. J.      1993   AIDS                          tuberculosis in Nairobi, Kenya                         Outcomes of interest not reported.

                                                         [Pulmonary tuberculosis and HIV seropositivity at
Brucker-Davis, F.   1993   Revue de Medecine Interne     the Principal Hospital of Dakar, Senegal]              Inadequate information on treatment regimens used.
                           American Journal of
                           Respiratory & Critical Care   Moxifloxacin versus ethambutol in the first 2
Burman, W.          2006   Medicine                      months of treatment for pulmonary tuberculosis         Outcomes of interest not reported.

                                                                                                                Individualized treatment regimens: patients received either 6 or 9
                                                                                                                months of treatment depending on culture-status at 2 months, INH
                                                                                                                resistance or INH intolerance. Also, 37 pts received mean 1 month of
                           American Journal of                                                                  Rifampin prior to enrollment in study, outcomes are not stratified by
                           Respiratory & Critical Care   Acquired rifamycin resistance with twice-weekly        rifampin vs rifabutin in the intensive phase. SEE ALSO JASMER 2004,
Burman, W.          2006   Medicine                      treatment of HIV-related tuberculosis                  WEINER 2005
                                                         Tuberculosis chemotherapy and sputum
                           East African Medical          conversion among HIV-seropositive and HIV-
Bwire, R.           1999   Journal                       seronegative patients in south-eastern Uganda          Outcomes of interest not reported.
                                                         Evaluation of a directly observed six months fully
                                                         intermittent treatment regimen for tuberculosis in     Outcomes not stratified by treatment regimen (some patients received
Caminero, J. A.     1996   Thorax                        patients suspected of poor compliance                  ethambutol). SEE ALSO CAMINERO 2001
                           American Journal of           Exogenous reinfection with tuberculosis on a
                           Respiratory & Critical Care   European island with a moderate incidence of
Caminero, J. A.     2001   Medicine                      disease                                                Outcomes of interest not reported.
                                                         [Tuberculosis and HIV infection. Evaluation of
Carcaba, V.         1993   Revista Clinica Espanola      132 cases]                                             Inadequate description of treatment regimen.
                                                         Clinical presentation and survival of smear-positive
                           Memorias do Instituto         pulmonary tuberculosis patients of a university        Outcomes not stratified by treatment regimen; duration of treatment
Carvalho, A.        2002   Oswaldo Cruz                  general hospital in a developing country               (duration of rifampin varied).

                                                         Comparison of daily and twice-weekly regimens to
Castelo, A.         1989   Lancet                        treat pulmonary tuberculosis                           No HIV.
                                                         Tuberculous pericarditis in Tanzanian patients with
Cegielski, J. P.    1994   Tubercle & Lung Disease       and without HIV infection                             Inadequate description of treatment regimens.
                           American Journal of           Six-month supervised intermittent tuberculosis
                           Respiratory & Critical Care   therapy in Haitian patients with and without HIV      Outcomes (failure) were not microbiologically confirmed. Discrepancy
Chaisson, R. E.     1996   Medicine                      infection                                             between proven cases (n=100) and proven cure (n=110).
                                                         Tuberculosis in patients with the acquired
                           American Review of            immunodeficiency syndrome. Clinical features,         Outcomes not stratified by treatment regimen. Used clinical diagnoses
Chaisson, R. E.     1987   Respiratory Diseases          response to therapy, and survival                     of AIDS.
                                                         Factors associated with an increased case-fatality
                                                         rate in HIV-infected and non-infected South           Outcomes not stratified by treatment regimen. SEE ALSO
Churchyard, G. J.   2000   IJTLD                         African gold miners with pulmonary tuberculosis       MALLORY 2000.

                                                         Population differences in death rates in HIV-         Outcomes not stratified by drug regimen. Neither failure nor relapse
Ciglenecki, I.      2007   IJTLD                         positive patients with tuberculosis                   reported (only mortality). SEE ALSO MWINGA 2002
Colebunders, R.            American Review of            HIV infection in patients with tuberculosis in
L.                  1989   Respiratory Diseases          Kinshasa, Zaire                                       Non-rifampin regimen.
                                                         Relapse and mortality among HIV-infected and
                                                         uninfected patients with tuberculosis successfully
                                                         treated with twice weekly directly observed therapy
Connolly, C.        1999   AIDS                          in rural South Africa                                 Utilized twice-weekly regimen. SEE ALSO DAVIES 1999

                                                         Impact of the human immunodeficiency virus            Neither failure nor relapse reported, only mortality. Insufficient data
                                                         epidemic on mortality among adults with               with respect to TB treatment regimens, duration, outcomes in HIV
Connolly, C.        1998   IJTLD                         tuberculosis in rural South Africa, 1991-1995         patients.
                                                         Epidemiology of tuberculosis in Galicia, Spain,
Cruz-Ferro, E.      2007   IJTLD                         1996-2005                                             Neither failure nor relapse reported. No data on treatment regimens.

                           Bulletin de la Societe de     [Antitubercular drug treatment failure and HIV
Daix, T.            2003   Pathologie Exotique           infection in Abidjan (Ivory Coast)]                   Inadequate description of treatment regimen, duration.
                                                         Follow-up of tuberculosis patients and link with
                           Medecine et Maladies          HIV infection in a French district, Gironde, 1995-
Daucourt, V.        2000   Infectieuses                  1996                                                  Individualized treatment regimens.
                                                        Rifabutin in combination with clofazimine,
                                                        isoniazid and ethambutol in the treatment of AIDS
                                                        patients with infections due to opportunist
Dautzenberg, B.   1991   Tubercle                       mycobacteria                                          MAI study.
                                                        Twice-weekly, directly observed treatment for
                                                        HIV-infected and uninfected tuberculosis patients:
Davies, GR.       1999   AIDS                           cohort study in rural South Africa                    Utilized twice-weekly regimen. SEE ALSO CONNOLLY 1999
                                                        Factors associated with treatment failure, dropout,
de Albuquerque,                                         and death in a cohort of tuberculosis patients in
M.                2007   Cadernos de Saude Publica      Recife, Pernambuco State, Brazil                      Outcomes not stratified by HIV status.

                                                        Treatment of tuberculosis in HIV-infected persons
Dean, G. L.       2002   AIDS                           in the era of highly active antiretroviral therapy    Outcomes not stratified by treatment regimen; individualized regimens.
                         Pediatric AIDS and HIV
Della Negra, M.   1994   Infection                      Tuberculosis in pediatric AIDS patients               Outcomes not stratified by treatment regimen.
                         Indian Journal of Public       Epidemiology of HIV infection among
Dey, S. K.        2003   Health                         tuberculosis patients in Calcutta                     Neither failure nor relapse reported.
                                                        Cases of human immunodeficiency virus infection
                         Journal of the Indian          and tuberculosis--early experiences of different
Dey, S. K.        2003   Medical Association            aspects                                               Neither failure nor relapse reported. SEE DEY 2003.

                         Journal of Infectious          Outcome of HIV-associated tuberculosis in the era     Outcomes not stratified by treatment regimen, nor duration;
Dheda, K.         2004   Diseases                       of highly active antiretroviral therapy               individualized treatment regimens.

                         Revista Cubana de                                                                    Outcomes not stratified by treatment regimen (some patients received
Diaz Jidy, M.     1996   Medicina Tropical              [Tuberculosis and HIV coinfection in Cuba]            ethambutol) SEE ALSO TORRES PENA.
Diez Ruiz                                               [Results of anti-tuberculosis treatment in six
Navarro, M.       2001   Medicina Clinica               autonomous regions in Spain]                          Outcomes not stratified by treatment regimen.
                                                        Epidemiology and clinical features of tuberculosis
                                                        in immigrants at an infectious diseases department    Outcomes not stratified by treatment regimen; inadequate information
Diz, S.           2007   IJTLD                          in Madrid                                             on treatment regimens used; outcomes not stratified by HIV status.
                                                        Relapse in persons treated for drug-susceptible
                                                        tuberculosis in a population with high coinfection
                                                        with human immunodeficiency virus in New York
Driver, C. R.     2001   Clinical Infectious Diseases   City                                                  Individualized treatment regimens. SEE ALSO Li 2005
                                                    Tuberculosis in patients infected with human
                        Quarterly Journal of        immunodeficiency virus 1. A retrospective
Dupon, M.        1992   Medicine                    multicentre study of 123 cases in France               Outcomes not stratified by treatment duration.
                        Medecine et Maladies        [Outcome of patients with tuberculosis and AIDS
Eholie, S. P.    1999   Infectieuses.               in Abidjan (Ivory Coast)]                              Not all cases of TB were microbiologically confirmed.

                                                    A randomized, double-blind, placebo-controlled
                        The Journal of Infectious   trial of the use of prednisolone as an adjunct to
Elliott, A.      2004   Diseases                    treatment in HIV-1-associated pleural tuberculosis     Extra-pulmonary TB without microbiologically proven outcomes.
                        Quarterly Journal of        Use of prednisolone in the treatment of HIV-
Elliott, A.      1992   Medicine                    positive tuberculosis patients                         Outcomes not stratified by treatment regimen.
                        Transactions of the Royal   The impact of human immunodeficiency virus on
                        Society of Tropical         mortality of patients treated for tuberculosis in a
Elliott, A.      1995   Medicine & Hygiene          cohort study in Zambia                                 Outcomes not stratified by treatment regimen.
                                                    The impact of human immunodeficiency virus on
                                                    response to treatment and recurrence rate in
                        Journal of Tropical         patients treated for tuberculosis: two-year follow-    Outcomes not stratified by regimen. SEE ALSO ELLIOTT 1995
Elliott, A.      1995   Medicine & Hygiene          up of a cohort in Lusaka, Zambia                       TRANS ROYAL SOC TMH.
                                                    Treatment results of DOTS in 1797 Sudanese
                                                    tuberculosis patients with or without HIV co-
El-Sony, A. I.   2002   IJTLD                       infection                                              Outcomes not stratified by treatment regimen.

Engohan                                             [Epidemiology of childhood tuberculosis in
Alloghe, E.      2006   Medecine Tropicale          Libreville, Gabon from 1997 to 2001]                   Inadequate information on treatment regimens.

                        American Review of          The influence of human immunodeficiency virus
Eriki, P. P.     1991   Respiratory Diseases        infection on tuberculosis in Kampala, Uganda           Outcomes not stratified by treatment regimen.
                        Journal of Acquired         Human immunodeficiency virus infection in
                        Immune Deficiency           children with tuberculosis in Santo Domingo,
                        Syndromes & Human           Dominican Republic: prevalence, clinical findings,
Espinal, M. A.   1996   Retrovirology               and response to antituberculosis treatment             Only 1 HIV positive patient had microbiologically confirmed TB.
                                                    [Survival of patients with HIV-related tuberculosis.
Falques                 Revista Espanola de Salud   Study of mortality during the first 9 months of
Casanovas, M.    1999   Publica                     treatment]                                             Neither failure nor relapse reported.
                                                      Effect of post-treatment isoniazid on prevention
                                                      of recurrent tuberculosis in HIV-1-infected
Fitzgerald, D. W.   2000   Lancet                     individuals: a randomised trial                        Casess & outcomes were not all microbiologically confirmed.
                                                      Influence of highly active anti-retroviral therapy
Garcia de Olalla,                                     (HAART) on the natural history of extra-
P.                  2002   IJTLD                      pulmonary tuberculosis in HIV patients                 Inadequate description of treatment regimen.

Garcia-Garcia,             Archives of Internal       Clinical consequences and transmissibility of drug-
M. L.               2000   Medicine                   resistant tuberculosis in southern Mexico              Outcomes not reported by HIV status.

Garcia-Ordonez,                                       Recurrent tuberculosis in patients with coinfection
M. A.               2003   Revista Clinica Espanola   by HIV                                                 Individualized treatment regimens.

                                                      High mortality rates among patients with
Garin, B.           1997   Lancet                     tuberculosis in Bangui, Central African Republic       Letter
                           Journal of Acquired        Changing clinical presentation and survival in HIV-
                           Immune Deficiency          associated tuberculosis after highly active
Girardi, E.         2001   Syndromes                  antiretroviral therapy                                 Individualized treatment regimens. SEE ALSO PALMIERI 1999

                                                      Cohort study of HIV-positive and HIV-negative
                                                      tuberculosis, Nairobi, Kenya: comparison of
Githui, W.          1992   Tubercle & Lung Disease    bacteriological results                                Inadequate data regarding HIV status & treatment outcomes.

                                                      Patterns of initial and acquired antituberculosis
Glynn, J. R.        1995   Lancet                     drug resistance in Karonga District, Malawi            Outcomes not stratified by HIV status, nor by treatment regimens.

                                                      Rifabutin for the treatment of newly-diagnosed
Gonzalez-                                             pulmonary tuberculosis: a multinational,
Montaner, L. J.     1994   Tubercle & Lung Disease    randomized, comparative study versus Rifampicin        No patients with HIV.
                                                      Effectiveness of cotrimoxazole prophylaxis on
                                                      mortality in adults with tuberculosis in rural South
Grimwade, K.        2005   AIDS                       Africa                                                 Outcomes not stratified by HIV status.
                           Archives of Internal       Mycobacteremia in patients with the acquired
Grinsztejn, B.      1997   Medicine                   immunodeficiency syndrome                              No description of treatment regimen.
                                                      Clinical predictors for death in HIV-positive and
                                                      HIV-negative tuberculosis patients in Guinea-
Gustafson, P.       2007   Infection                  Bissau                                                 Neither failure nor relapse reported, only mortality.
                                                       Double blind randomised placebo controlled trial
                                                       of adjunctive prednisolone in the treatment of
                           Heart (British Cardiac      effusive tuberculous pericarditis in HIV
Hakim, J.           2000   Society)                    seropositive patients                                     EPTB without microbiologically confirmed outcomes.
                                                       Isoniazid plus sulphadoxine-pyrimethamine can
                                                       reduce morbidity of HIV-positive patients treated
Haller, L.          1999   Chemotherapy                for tuberculosis in Africa: a controlled clinical trial   Outcomes not stratified by treatment regimen.
                                                       'Smear-negative' pulmonary tuberculosis in a
                                                       DOTS programme: poor outcomes in an area of
Hargreaves, N. J.   2001   IJTLD                       high HIV seroprevalence                                   Outcomes not stratified by HIV status nor treatment regimens.

                                                       Regimen containing short-term rifampicin for
Harries, A. D.      1995   Lancet                      pulmonary tuberculosis in HIV-infection                   Letter.

                                                       Deaths from tuberculosis in sub-Saharan African
Harries, A. D.      2001   Lancet                      countries with a high prevalence of HIV-1                 Not a study.
                                                       Efficacy of an unsupervised ambulatory treatment
                                                       regimen for smear-negative pulmonary tuberculosis         Outcomes not stratified by HIV status. See also BANDA IJTLD 2000,
Harries, A. D.      1999   IJTLD                       and tuberculous pleural effusion in Malawi                KANGOMBE 2000, KANGOMBE 2004, HARRIES 1999 TRSTMH.
                                                       Is oral intermittent initial phase anti-tuberculosis
                                                       treatment associated with higher mortality in high
Harries, A. D.      2001   IJTLD                       HIV-prevalent areas in sub-Saharan Africa?                Outcomes not stratified by HIV status.
                                                       High early death rate in tuberculosis patients in
Harries, A. D.      2001   IJTLD                       Malawi                                                    Outcomes not stratified by HIV status (no HIV testing done).
                                                       Treatment outcome of patients with smear-
                           Transactions of the Royal   negative and smear-positive pulmonary
                           Society of Tropical         tuberculosis in the National Tuberculosis Control         Outcomes not stratified by HIV status. KANGOMBE 2000,
Harries, A. D.      1999   Medicine & Hygiene          Programme, Malawi                                         KANGOMBE 2004, HARRIES 1999 IJTLD, BANDA 2000
                           Transactions of the Royal
                           Society of Tropical         Relapse and recurrent tuberculosis in the context
Harries, A. D.      2000   Medicine & Hygiene          of a national tuberculosis control programme              Outcomes not stratified by HIV status.
                                                       Increased recurrence of tuberculosis in HIV-1-            Individualized treatment regimens (pts were treated until culture
Hawken, M.          1993   Lancet                      infected patients in Kenya                                negative).
                                                       Comparison between human immunodeficiency
                           Memorias do Instituto       virus positive and negative patients with
Henn, L.            1999   Oswaldo Cruz                tuberculosis in Southern Brazil                           Outcomes not stratified by treatment regimen.
                          Archives of Disease in        Outcome of HIV infected children with culture
Hesseling, A. C.   2005   Childhood                     confirmed tuberculosis                                    Outcomes not stratified by treatment regimen.
                                                        Clinical aspects and treatment outcome in HIV-
Hongthiamthong,           Journal of the Medical        associated pulmonary tuberculosis: An experience
P.                 1994   Association of Thailand       from a Thai referral centre                               Individualized treatment regimens.

                                                        Clinical features and outcome in disseminated
Hsieh, S. M.       1998   AIDS                          mycobacterial diseases in AIDS patients in Taiwan         Insufficient data regarding treatment regimens.
                                                        Improved outcomes of HIV-1-infected adults with
                                                        tuberculosis in the era of highly active antiretroviral
Hung, C-C.         2003   AIDS                          therapy                                                   Outcomes not stratified by treatment regimen.
                          Journal of Acquired           Recurrence of tuberculosis in HIV-1-infected
                          Immune Deficiency             adults treated after rifamycin-based treatment and
Hung, C-C.         2003   Syndromes                     highly active antiretroviral therapy                      Letter.
                          Journal of Acquired           A pilot study of once-daily antiretroviral therapy
                          Immune Deficiency             integrated with tuberculosis directly observed
Jack, C.           2004   Syndromes                     therapy in a resource-limited setting                     Individualized treatment regimens.

                                                        Effects of the human immunodeficiency virus on            Outcomes of interest not reported, only mortality. No microbiologically
Jeena, P. M.       1996   Tubercle & Lung Disease       tuberculosis in children                                  confirmed TB at all.
                                                        Risk factors for relapse in human
                                                        immunodeficiency virus type 1 infected adults with        Nested case-control within an RCT, cases were pts who relapsed SEE
Johnson, J. L.     1997   IJTLD                         pulmonary tuberculosis                                    OKWERA 1994 WHALEN 1996
                          American Journal of           A prospective evaluation of antituberculosis
                          Respiratory & Critical Care   therapy in patients with human immunodeficiency
Jones, B. E.       1994   Medicine                      virus infection                                           Outcomes not stratified by drug regimen

                          Transactions of the Royal     High mortality rates in tuberculosis patients in
                          Society of Tropical           Zomba Hospital, Malawi, during 32 months of               Outcomes not stratified by drug regimen SEE ALSO HARRIES 1999
Kang'ombe, C.      2000   Medicine & Hygiene            follow-up                                                 and KANGOMBE 2004
                                                        Long-term outcome in patients registered with
                                                        tuberculosis in Zomba, Malawi: mortality at 7 years       Outcomes not stratified by TB treatment regimen SEE ALSO
Kang'ombe, C. T.   2004   IJTLD                         according to initial HIV status and type of TB            HARRIES 1999 and KANGOMBE 2000
                          American Journal of           Tuberculosis mortality, drug resistance, and
                          Tropical Medicine &           infectiousness in patients with and without HIV           Outcomes not stratified by drug regimen. Significant number with
Kawai, V.          2006   Hygiene                       infection in Peru                                         MDRTB (18%)
                         American Review of             Early bactericidal and sterilizing activities of
Kennedy, N.       1993   Respiratory Disease            ciprofloxacin in pulmonary tuberculosis              Outcomes of interest not reported.

                         Journal of Health              HIV-associated tuberculosis among a cohort of
Kennedy, S. B.    2002   Population and Nutrition       heterosexual discordant couples in Lusaka, Zambia    Inadequate description of treatment regimen.
                                                        Smear positive pulmonary tuberculosis in a prison
                                                        setting: experience in the penal camp of Bouake,
Koffi, N.         1997   IJTLD                          Ivory Coast                                          Outcomes not stratified by HIV status.

Korzeniewska-            Canadian Medical               Spectrum of tuberculosis in patients with HIV
Kosela, M.        1992   Association Journal            infection in British Columbia: Report of 40 cases    Individualized treatment regimens.
                                                        Risk factors for mortality among patients with
Kourbatova, E.           European Journal of            extrapulmonary tuberculosis at an academic inner-
V.                2006   Epidemiology                   city hospital in the US                              Outcomes not stratified by treatment regimen, nor duration.

                                                        AIDS and tuberculosis in Spain. A report of 140
Laguna, F.        1991   Journal of Infection           cases                                                Outcomes not stratified by treatment regimen.

                         Infection Control &            Management and outcome of tuberculosis in two
L'Ecuyer, P. B.   1998   Hospital Epidemiology          St Louis hospitals, 1988 to 1994                     Outcomes not stratified by HIV status, duration.
                                                        Spinal tuberculosis in patients with human
                                                        immunodeficiency virus infection: clinical
Leibert, E.       1996   Tubercle & Lung Disease        presentation, therapy and outcome                    EPTB without microbiologically confirmed outcomes.
                                                        Progression of human immunodeficiency virus
                         American Journal of            infection in patients with tuberculosis disease. A   Outcomes of interest not reported. Outcomes not stratified by regimen,
Leroy, V.         1997   Epidemiology                   cohort study in Bordeaux, France, 1988-1994          duration.
                                                        Relapse and acquired rifampin resistance in HIV-
                                                        infected patients with tuberculosis treated with
                                                        rifampin- or rifabutin-based regimens in New York    Outcomes not stratified by treatment regimen, nor duration. SEE
Li, J.            2005   Clinical Infectious Diseases   City, 1997-2000                                      ALSO DRIVER 2001

                         Revista Da Sociedade           Characteristics of pulmonary tuberculosis in HIV
                         Brasileira de Medicina         seropositive and seronegative patients in a
Liberato, I.      2004   Tropical                       Northeastern region of Brazil                        Outcomes of interest not reported.
                                                      Factors determining the outcome of treatment of
                                                      adult smear-positive tuberculosis cases in The       Outcomes not stratified by HIV status (only cure, but even in the cure
Lienhardt, C.      1998   IJTLD                       Gambia                                               5 pts outcomes are unaccounted for).
                                                      Influence of treatment and immunological
Lopez-Cortes, L.                                      recovery on tuberculosis relapses in HIV-infected
F.                 2005   IJTLD                       patients                                             Outcomes not stratified by treatment regimen.

                                                      Tuberculosis in non-Haitian patients with acquired
Louie, E.          1986   Chest                       immunodeficiency syndrome                            Outcomes not stratified by treatment regimen.
                                                      Human immunodeficiency virus type-1 infection in
                                                      Zambian children with tuberculosis: Changing
                                                      seroprevalence and evaluation of a thioacetazone-
Luo, C.            1994   Tubercle and Lung Disease   free regimen                                         Outcomes of interest not reported, only mortality.

                                                      HIV-1 co-infection in children hospitalised with
Madhi, S. A.       2000   IJTLD                       tuberculosis in South Africa                         Not a treatment study.

                                                      Outcomes of tuberculosis patients who start
                                                      antiretroviral therapy under routine programme       Outcomes not stratified by treatment regimen, duration of treatment,
Makombe, S. D.     2007   IJTLD                       conditions in Malawi                                 variable drug regimen.
                                                                                                           Insufficient data for outcomes of HIV-positive pts: rates of failure and
                                                      Tuberculosis and human immunodeficiency virus        relapse only given for pulmonary TB, but no data on how many pulmonary
                                                      infection in west Burkina Faso: clinical             TB lost to follow-up pre and post treatment, how many pulmonary TB
Malkin, J. E.      1997   IJTLD                       presentation and clinical evolution                  died pre and post treatment.

                                                      The impact of HIV infection on recurrence of         Outcomes not stratified by duration of treatment. See also
Mallory, K. F.     2000   IJTLD                       tuberculosis in South African gold miners            CHURCHYARD 2000


                          Journal of Acquired         Survival rate and risk factors of mortality among
                          Immune Deficiency           HIV/tuberculosis-coinfected patients with and
Manosuthi, W.      2006   Syndromes                   without antiretroviral therapy                       Individualized treatment regimens.
                                                      Predictors of adherence to tuberculosis treatment
                                                      in a supervised therapy programme for prisoners
                          European Respiratory        before and after release. Study Group of
Marco, A.          1998   Journal                     Adherence to Tuberculosis Treatment of Prisoners     Outcomes not stratified by HIV status.
                                                       Relapse after short-course chemotherapy of
                                                       patients with sputum smear-positive pulmonary
                                                       tuberculosis under routine conditions with
                                                       additional information on side effects and contact
Martinez, F. D.   1996   Tubercle & Lung Disease       tracing                                                No HIV testing.

                                                       [Epidemiologic situation of tuberculosis under the
                                                       influence of HIV in the health area of Ibiza and       Outcomes not stratified by treatment regimen, inadequate information
Martinez, M.      1998   Atencion Primaria             Formentera (1987-1993)]                                on treatment regimens used.

                                                       Persistent replication of human immunodeficiency
Mayanja-Kizza,           Clinical & Diagnostic         virus type 1 despite treatment of pulmonary
H.                2005   Laboratory Immunology         tuberculosis in dually infected subjects               Outcomes of interest not reported.
                                                       Immunoadjuvant prednisolone therapy for HIV-
Mayanja-Kizza,           Journal of Infectious         associated tuberculosis: a phase 2 clinical trial in
H.                2005   Diseases                      Uganda                                                 Inadequate description of treatment regimen, duration.
                         Transactions of the Royal     Double-blind placebo-controlled trial of
                         Society of Tropical           Mycobacterium vaccae immunotherapy for
Mayo, R. E.       2000   Medicine & Hygiene            tuberculosis in KwaZulu, South Africa, 1991-97         Outcomes not stratified by HIV status.

                         Cellular & Molecular          Pulmonary tuberculosis mortality risks in a cohort
Mayor, A. M.      2001   Biology                       of HIV/AIDS patients in Puerto Rico                    Inadequate description of treatment regimen, duration.

                         South African Medical         Mortality in patients treated for tuberculous
Mayosi, B. M.     2008   Journal.                      pericarditis in sub-Saharan Africa                     Outcomes not stratified by HIV status, duration
                         American Journal of           Efficacy and safety of rifabutin in the treatment of
                         Respiratory & Critical Care   patients with newly diagnosed pulmonary
McGregor, M. M.   1996   Medicine                      tuberculosis                                           No HIV.
                                                       Tuberculosis and HIV infection association in a
                                                       rural district of Northern Uganda: Epidemiological
Migliori, G. B.   1992   Tubercle & Lung Disease       and clinical considerations                            Outcomes not stratified by regimen.
                                                       Integration of tuberculosis treatment in a
                                                       community-based home care programme for
Miti, S.          2003   IJTLD                         persons living with HIV/AIDS in Ndola, Zambia          Unclear if patients had HIV or not.
                                                       The impact of acquired immunodeficiency
                         Papua New Guinea Medical      syndrome (AIDS) on tuberculosis control in Papua
Mondia, P. W.     1990   Journal                       New Guinea                                             Editorial.
                                                       Prevalence, incidence and mortality associated with
                                                       tuberculosis in HIV-infected patients initiating
Moore, David     2007   AIDS                           antiretroviral therapy in rural Uganda                Outcomes not stratified by drug regimen, duration of treatment.
                                                       Treatment of tuberculosis in HIV-infected
                                                       patients: safety and antiretroviral efficacy of the
Moreno, S.       2001   AIDS                           concomitant use of ritonavir and rifampin             Outcomes of interest not reported.
                                                       [Tuberculosis and HIV/AIDS co-infection in
M'Pemba                                                children: experience carried out in paediatric
Loufoua Lemay,          Bulletin de la Societe de      service of the teaching hospital of Brazzaville,
A. B.            2007   Pathologie Exotique            Republic of Congo (1995-2004)]                        Outcomes of interest not reported.
                                                       Impact of HIV infection on the development,
                                                       clinical presentation, and outcome of tuberculosis
Mukadi, Y. D.    1997   AIDS                           among children in Abidjan, Cote d'Ivoire              Excluded, not 100% confirmation of TB
                                                       Mycobacterium vaccae (SRL172) immunotherapy
                                                       as an adjunct to standard antituberculosis
                                                       treatment in HIV-infected adults with pulmonary       Outcomes not stratified by treatment regimen in HIV (+) pts. SEE also
Mwinga A.        2002   Lancet                         tuberculosis: a randomised placebo-controlled trial   CIGLENECKI 2007
                        American Journal of
                        Respiratory & Critical Care    Treatment outcomes of patients with HIV and           Individualized treatment regimens, highly variable duration of
Nahid, P.        2007   Medicine                       tuberculosis.[see comment]                            treatment.
                                                       Pulmonary tuberculosis in Guinea-Bissau: clinical
                                                       and bacteriological findings, human
                                                       immunodeficiency virus status and short term
Naucler, A.      1996   Tubercle & Lung Disease        survival of hospitalized patients                     Outcomes of interest not reported.
                                                       [Tuberculosis and HIV infection. Prospective
Navarro, V.      1993   Revista Clinica Espanola       study of 215 patients.]                               Outcomes not stratified by treatment regimen
                                                       Risk factors for relapse and acquired rifamycin
                                                       resistance after directly observed tuberculosis
                                                       treatment: a comparison by HIV serostatus and
Nettles, R. E.   2004   Clinical Infectious Diseases   rifamycin use                                         Variable duration of rifampin use (28-48 weeks).

                                                       High mortality and severe immunosuppression in
                        Scandinavian Journal of        hospitalized patients with pulmonary tuberculosis
Norrgren, H.     2001   Infectious Diseases            and HIV-2 infection in Guinea-Bissau                  Outcomes not stratified by regimen.
                                                       Gender and HIV-associated pulmonary
                                                       tuberculosis: Presentation and outcome at one year
Nsubuga, P.      2002   BMC Pulmonary Medicine         after beginning antituberculosis treatment in         Already included in JOHNSON 2000.
                                                 Uganda


                                                 Cohort study of human immunodeficiency virus
                          American Review of     infection in patients with tuberculosis in Nairobi,   Individualized treatment regimens (could be modified based on
Nunn, P.           1992   Respiratory Disease    Kenya: Analysis of early (6-month) mortality          resistance, failure, clinical picture).
                                                 Reported childhood tuberculosis treatment
                                                 outcomes, Gaborone and Francistown, Botswana,         Outcomes not stratified by treatment regimen, inadequate information
Oeltmann, C. B.    2008   IJTLD                  1998-2002                                             on treatment regimens used. Outcomes not stratified by HIV status.
                                                 Randomised trial of thiacetazone and rifampicin-      Outcomes of interest not reported, only mortality and early (2-month)
                                                 containing regimens for pulmonary tuberculosis in     sputum results, but not failure and no relapse data. Deaths on treatment
                                                 HIV-infected Ugandans. The Makerere University-       not stratified by exact drug regimen. SEE JOHNSON 1997 IJTLD
Okwera, A.         1994   Lancet                 Case Western University Research Collaboration        WHALEN 1996

                                                 Co-administration of rifampin and nevirapine in
Oliva, J.          2003   AIDS                   HIV-infected patients with tuberculosis               Letter. Also variable duration of treatment (median 9, range 7-21)

                                                 Treatment of tuberculosis in a rural area of Haiti:
                                                 Directly observed and non-observed regimens. The
Olle-Goig, J. E.   2001   IJTLD                  experience of Hopital Albert Schweitzer               Excluded, not 100% confirmation of TB
                                                                                                       Judged to be too poor quality by 3 reviewers due to very poor
                                                                                                       compliance amongst patients, with no confirmation of duration of
                                                                                                       prescribed treatment and high loss to f/u. Atypical outcomes: death
                                                 Immunotherapy with Mycobacterium vaccae as an         and sputum clearance at 10-14 months (treatment duration was 8
                                                 addition to chemotherapy for the treatment of         months), only 9 HIV(+) pts who received placebo. Although all HIV
                                                 pulmonary tuberculosis under difficult conditions     (+) pts who rcvd placebo were f/u: 6 died (dont know if while on
Onyebujoh, P. C.   1995   Respiratory Medicine   in Africa                                             therapy or post-Rx), and 3 were sputum pos at 10-14 month f/u.
                                                 The relationship between delayed or incomplete
Pablos Mendez,                                   treatment and all-cause mortality in patients with
A.                 1996   JAMA                   tuberculosis                                          Outcomes not given by treatment duration.
                                                      Negative predictors of survival in HIV-infected
                                                      patients with culture-confirmed pulmonary
Palmieri, F.        1999   Infection                  tuberculosis                                          Individualized regimens.
                                                      Safety and antiretroviral effectiveness of
                           Journal of Acquired        concomitant use of rifampicin and efavirenz for
                           Immune Deficiency          antiretroviral-naive patients in India who are        Poor quality study with respect to TB outcomes: Most patients did not
Patel, A.           2004   Syndromes                  coinfected with tuberculosis and HIV-1                have proven TB.
                                                      The epidemiology of tuberculosis in patients with
Perez Perdomo,                                        AIDS in Puerto Rico: morbidity and survival,          Outcomes not stratified by treatment regimen, no information on
R.                  2000   IJTLD                      1981-1998                                             treatment regimens used.
                                                      Increased mortality and tuberculosis treatment
                                                      failure rate among human immunodeficiency virus
                                                      (HIV) seropositive compared with HIV
                                                      seronegative patients with pulmonary tuberculosis
                           American Review of         treated with "standard" chemotherapy in Kinshasa,     Outcomes not stratified by exact drug regimen (outcomes grouped
Perriens, J. H.     1991   Respiratory Disease        Zaire                                                 together for pts who rcvd SH and those that received RHEZ).

                                                      Should pulmonary tuberculosis be an AIDS-
Perronne, C.        1992   Tubercle & Lung Disease    defining diagnosis in patients infected with HIV?     Outcomes not stratified by regimen (variable use of PZA).




                                                      [Tuberculosis in patients infected with the human
Perronne, C.        1988   Presse Medicale            immunodeficiency virus. 30 cases]                     Outcomes not stratified by duration of treatment.
                                                      Disease progression and survival following specific
                                                      AIDS-defining conditions: a retrospective cohort      Insufficient data with respect to TB treatment regimens, duration,
Petruckevitch, A.   1998   AIDS                       study of 2048 HIV-infected persons in London          outcomes.
                                                      [Excess mortality due to tuberculosis and factors
                                                      associated to death in and annual cohort of
Pina, J. M.         2006   Revista Clinica Espanola   patients diagnosed of tuberculosis]                   Outcomes not stratified by HIV status AND treatment regimens.
                         Archives of Internal           Relapse of tuberculosis after treatment in human
Pulido, F.        1997   Medicine                       immunodeficiency virus-infected patients             Outcomes not stratified by regimen.
                                                        Treatment outcomes by drug resistance and HIV
                                                        status among tuberculosis patients in Ho Chi Minh
Quy, H. T.        2006   IJTLD                          City, Vietnam                                        Outcomes not stratified by regimen.
                                                        Noncompliance with tuberculosis treatment by
                         Brazilian Journal of           patients at a tuberculosis and AIDS reference
Rabahi, M.F.      2002   Infectious Diseases            hospital in midwestern Brazil                        Outcomes not stratified by treatment regimen, nor duration.
                                                        The effect of micronutrient supplementation on
                                                        treatment outcome in patients with pulmonary
                         Tropical medicine &            tuberculosis: a randomized controlled trial in
Range N.          2005   international health           Mwanza, Tanzania                                     Outcomes of interest not reported, only 8 week treatment results.
                                                        The effect of multi-vitamin/mineral
                                                        supplementation on mortality during treatment of
                                                        pulmonary tuberculosis: a randomised two-by-two
Range, N.         2006   British Journal of Nutrition   factorial trial in Mwanza, Tanzania                  Inadequate description of treatment regimen, duration.

                                                        Impact of human immunodeficiency virus
                         Journal of Clinical            infection on abdominal tuberculosis in western
Rathi, P.         1997   Gastroenterology               India                                                EPTB without microbiologically confirmed outcomes.


                         Cardiovascular Journal of      The management of tuberculous pericardial
Reuter, H.        2007   Southern Africa                effusion: experience in 233 consecutive patients     Outcomes not stratified by HIV status.
                                                        Predictive markers of survival in HIV-seropositive
                                                        and HIV-seronegative Tanzanian patients with
Richter, C.       1995   Tubercle & Lung Disease        extrapulmonary tuberculosis                          Outcomes not stratified by drug regimen.

                         European Respiratory           The role of adherence in tuberculosis HIV-positive   Inadequate description of treatment regimen, duration. Outcomes not
Rocha, M.         2003   Journal                        patients treated in ambulatory regimen               stratified by regimen.
                                                        DOTS-based tuberculosis treatment and control
                         Bulletin of the World          during civil conflict and an HIV epidemic,
Rodger, A.J.      2002   Health Organization            Churachandpur District, India                        Excluded, not 100% confirmation of TB
                         Southeast Asian Journal of     The comparison of tuberculosis treatments: a short
Roosihermiatie,          Tropical Medicine & Public     course therapy and the directly observed short
B.                2000   Health                         course treatment (DOTS), East Java Province,         No HIV testing.
                                                         Indonesia



Ruiz-Navarro,             Archivos de                    Effects of HIV status and other variables on the
M.D.               2005   Bronconeumologia               outcome of tuberculosis treatment in Spain            Outcomes not given by treatment regimen, nor duration.

                          Journal of Acquired            Antiretroviral Therapy for HIV-Infected
Sanguanwongse,            Immune Deficiency              Tuberculosis Patients Saves Lives but Needs to Be
N.                 2008   Syndromes                      Used More Frequently in Thailand                      Individualized treatment regimens. Some pts included in Akkslip 2007.

                          East African Medical           Tuberculosis of the spine in children at Muhimbili
Sayi, E. N.        1995   Journal                        Medical Centre, Dar es Salaam                         No HIV testing.

                          Pediatric Infectious Disease   Recurrent culture-confirmed tuberculosis in human
Schaaf, H. S.      2005   Journal                        immunodeficiency virus-infected children              Outcomes not stratified by treatment regimen, nor duration.
                                                         Acute and long-term efficacy of antituberculous
                                                         treatment in HIV-seropositive patients with
Schurmann, D.      1993   Journal of Infection           tuberculosis: A study of 36 cases                     Outcomes not stratified by regimen.
                                                         Clinical course of human immunodeficiency virus
                          East African Medical           type 1 associated pulmonary tuberculosis during
Schwander, S. K.   1997   Journal                        short-course antituberculosis therapy                 Cohort already included, SEE SCHWANDER 1995 TLD


                                                         Micronutrient supplements and mortality of HIV-
                                                         infected adults with pulmonary TB: a controlled
Semba, R.          2007   IJTLD                          clinical trial                                        Outcomes of interest not reported, only mortality.

                                                         Community study of the relative impact of HIV-1       Outcome cultures could not be followed-up due to civil war for a large
Seng, R.           2002   AIDS                           and HIV-2 on intrathoracic tuberculosis               number of patients (correspondance with author).

                                                         Extrapulmonary tuberculosis in patients with
Shafer, R. W.      1991   Medicine                       human immunodeficiency virus infection                Outcomes not stratified by regimen.

                                                         Predictors of survival in HIV-infected tuberculosis
Shafer, R. W.      1996   AIDS                           patients                                              Outcomes of interest not reported.
                                                   The results of 9-month isoniazid-rifampin therapy
                         American Review of        for pulmonary tuberculosis under program
Slutkin, G.       1988   Respiratory Disease       conditions in San Francisco                           No HIV.
                         New England Journal of    Treatment of tuberculosis in patients with
Small, P. M.      1991   Medicine                  advanced human immunodeficiency virus infection       Outcomes not stratified by regimen.

                                                   Characteristics of tuberculosis in HIV-infected       Outcomes not stratified by treatment regimen (15 cases had to have
Soriano, E.       1988   AIDS                      patients: a case-control study                        their TB meds discontinued and these were treated for a longer time).

                                                   Mortality in a large tuberculosis treatment trial:
Sterling, T.      2006   IJTLD                     modifiable and non-modifiable risk factors            Individualized regimens. TBTC 22 See also VERNON.
                                                   Relapse rates after short-course (6-month)
                                                   treatment of tuberculosis in HIV-infected and         Individualized treatment: HIV patients time to complete therapy was
Sterling, T. R.   1999   AIDS                      uninfected persons                                    well over 180 days with a large range.
                                                   Survival in a cohort of human immunodeficiency
                                                   virus-infected tuberculosis patients in New York
                         Archives of Internal      City. Implications for the expansion of the AIDS
Stoneburner, R.   1992   Medicine                  case definition                                       No description of treatment regimen, duration.
                                                   Initiation of antiretroviral therapy in advanced
Sungkanuparph,                                     AIDS with active tuberculosis: clinical experiences
S.                2006   Journal of Infection      from Thailand                                         Individualized regimens.
                                                   Miliary tuberculosis in human immunodeficiency
                                                   virus infected patients not on antiretroviral
                         Journal of Postgraduate   therapy: Clinical profile and response to short-
Swaminathan, S.   2007   Medicine                  course chemotherapy                                   Some patients already included in SWAMINATHAM 2008.


                         Journal of Infectious     Human immunodeficiency virus infection in             Outcomes not stratified by regimen. Individualized regimens (some
Theuer, C. P.     1990   Diseases                  tuberculosis patients                                 could have been extended).
                                                   Predictors of relapse among pulmonary
                                                   tuberculosis patients treated in a DOTS
Thomas, A.        2005   IJTLD                     programme in South India                              No HIV.

                         New England Journal of    Dexamethasone for the treatment of tuberculous
Thwaites, G.      2004   Medicine                  meningitis in adolescents and adults                  EPTB without microbiologically proven outcomes.

                         Annals of Tropical
Topley, J. M.     1998   Paediatrics               Tuberculous meningitis and co-infection with HIV      Non-standardized regimens. All pts received corticosteroids.
                           Boletin de la Oficina          [Human immunodeficiency virus infection and           Outcomes not stratified by drug regimen (some may have received
Torres Pena, R.     1995   Sanitaria Panamericana         tuberculosis in Cuba]                                 ethambutol instead of streptomycin) SEE ALSO Diaz Jidy.
                                                          Impact of human immunodeficiency virus                Outcomes not stratified by HIV status AND treatment regimens (just
                                                          infection on the outcome of treatment and survival    give for HIV positive patients,or by smear and TB-hx status; but not
van den Broek, J.   1998   IJTLD                          of tuberculosis patients in Mwanza, Tanzania          the three combined)
                                                          Incidence of tuberculosis and survival after its
van der Sande,                                            diagnosis in patients infected with HIV-1 and         Outcomes of interest not reported. Inadequate description of treatment
M. A.               2004   AIDS                           HIV-2                                                 regimens.

                                                          HIV care and treatment factors associated with
Varma, J. K.        2008   Unpublished                    improved survival during TB treatment in Thailand     Individualized treatments with highly variable duration of treatment.
                                                          Acquired rifamycin monoresistance in patients
                                                          with HIV-related tuberculosis treated with once-
                                                          weekly rifapentine and isoniazid. Tuberculosis
Vernon, A.          1999   Lancet                         Trials Consortium                                     Individualized regimens. See also Sterling 2006.

                                                          Survival and relapse rate of tuberculosis patients
Vree, M.            2007   IJTLD                          who successfully completed treatment in Vietnam       HIV neg or unknown.


                           The Journal of infectious      Pentoxifylline in human immunodeficiency virus-
Wallis, R.          1998   diseases                       positive tuberculosis: safety at 4 years              Letter.
                                                          Pentoxifylline therapy in human immunodeficiency
                           The Journal of infectious      virus-seropositive persons with tuberculosis: a       Poor quality because of discrepancies in reported outcomes between
Wallis, R.          1996   diseases                       randomized, controlled trial                          letter to editor 1998 and this article.
                                                          Association between acquired rifamycin resistance
                                                          and the pharmacokinetics of rifabutin and isoniazid
Weiner, M.          2005   Clinical Infectious Diseases   among patients with HIV and tuberculosis              Pharmacokinetic sub-study of TBTC 23.

                                                          Paradoxical worsening of tuberculosis in HIV-         Individualized regimens (could be extended if not converted by 3
Wendel, K. A.       2001   Chest                          infected persons                                      months). Outcomes not stratified by regimen, duration.


                                                          Site of disease and opportunistic infection predict
Whalen, C.          1997   AIDS                           survival in HIV-associated tuberculosis               Inadequate description of treatment regimen, duration.
                                                      Predictors of survival in human immunodeficiency
                                                      virus-infected patients with pulmonary
                        American Journal of           tuberculosis. The Makerere University-Case
                        Respiratory & Critical Care   Western Reserve University Research                   Outcomes not stratified by treatment regimen. SEE OKWERA 1994,
Whalen, C.       1996   Medicine                      Collaboration                                         JOHNSON 1997
                                                      Impact of pulmonary tuberculosis on survival of
                                                      HIV-infected adults: a prospective epidemiologic
Whalen, C.       2000   AIDS                          study in Uganda                                       Reported as JOHNSON 2000.
                                                      Efficacy of trimethoprim-sulphamethoxazole
                                                      prophylaxis to decrease morbidity and mortality in
                                                      HIV-1-infected patients with tuberculosis in          Unclear how many pts completed treatment and were cured (only
                                                      Abidjan, Cote d'Ivoire: a randomised controlled       provide % cure of those that completed treatment), and how many lost
Wiktor, S.       1999   Lancet                        trial                                                 to f/u pre or post treatment.

                        South African Medical         HIV-related tuberculosis in South Africa--clinical
Wilkinson, D.    1996   Journal                       features and outcome                                  Inadequate description of treatment regimen, duration.


                        Journal of Tropical           Pediatric tuberculosis in rural South Africa--value
Wilkinson, D.    1998   Pediatrics                    of directly observed therapy                          Outcomes of interest not reported.

                        Annales de la Société Belge   [Tuberculosis and anti-HIV seropositivity in
Willame, J. C.   1988   de Médecine Tropicale         Kinshasa, Zaire]                                      Outcomes of interest not reported.
                                                      Diagnosing smear-negative tuberculosis using case
                                                      definitions and treatment response in HIV-infected    Insufficient data with respect to TB treatment outcomes. Only gives 8
Wilson, D.       2006   IJTLD                         adults                                                week outcomes.
                                                      Three-year follow-up of patients with pulmonary       Individualized regimens (according to email from author, 2 pts kept on
Winqvist, N.     2000   IJTLD                         tuberculosis in Guinea-Bissau, West Africa            treatment past 9 months as they had crepitations on exam).

                        Canadian Medical              Outcome of pulmonary tuberculosis treatment in        Outcomes not provided by treatment regimen and duration. Variable
Wobeser, W.      1999   Association Journal           the tertiary care setting--Toronto 1992/93            treatment regimens and duration. (for HIV patients mean 63 wks)
                                                      Comparison of AIDS progression and survival in
                                                      persons with pulmonary versus extrapulmonary
Wohl, A. R.      2001   AIDS Patient Care & STDs      tuberculosis in Los Angeles                           Outcomes of interest not reported.
                                                    Direct observation of treatment for tuberculosis: a
                        Tropical Medicine &         randomized controlled trial of community health
Wright, J.       2004   International Health        workers versus family members                         No HIV testing.


Bellamy R.       2006   ClinicalEvidence.BMJ.Com.    Managing tuberculosis in people with HIV             Review article used for additional references
                                                    Should tuberculosis treatment and control be
                        European Respiratory        addressed differently in HIV-infected and -
Dlodlo, RA.      2005   Journal.                    uninfected individuals?                               Review article used for additional references
                                                    A review of efficacy studies of 6-month short-
                                                    course therapy for tuberculosis among patients
                        Clinical Infectious         infected with human immunodeficiency virus:
El-Sadr, W. M.   2001   Diseases.                   differences in study outcomes                         Review article used for additional references
                                                     Effects of human immunodeficiency virus
                        Clinical Infectious         infection on recurrence of tuberculosis after
Korenromp, EL.   2003   Diseases.                   rifampin-based treatment: an analytical review        Review article used for additional references


                        Journal of Infectious       Treatment Options for HIV-Associated
Onyebujoh, PC.   2007   Diseases                    Tuberculosis                                          Review article used for additional references

								
To top